<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; SuperGen Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/supergen-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(CELG) Celgene Analyst Maintains Neutral Rating With $58 Target Price</title>
		<link>http://www.stockbloghub.com/2010/08/22/celg-celgene-analyst-maintains-neutral-rating-with-58-target-price/48443</link>
		<comments>http://www.stockbloghub.com/2010/08/22/celg-celgene-analyst-maintains-neutral-rating-with-58-target-price/48443#comments</comments>
		<pubDate>Sun, 22 Aug 2010 23:16:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Midas Inc.]]></category>
		<category><![CDATA[SuperGen Inc]]></category>
		<category><![CDATA[SUPG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48443</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Celgene Corporation (CELG) with a target price of $58. Celgene, founded in 1986 and headquartered in Summit, NJ, focuses on the discovery, development and commercialization of drugs in the areas of cancer and immune/inflammatory diseases. The company’s key growth engine is Revlimid, currently approved for myelodysplastic syndrome (MDS) and second-line multiple myeloma (MM). The company is expanding its label into other indications. The drug, which is approved in approximately 50 countries for treating patients suffering from MM who have received at least one prior therapy in combination with dexamethasone, recently received marketing approval in Japan for the same indication. Another important growth driver at Celgene is Vidaza, which is approved for the treatment of MDS. The third marketed product at Celgene is Thalomid, approved ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/22/celg-celgene-analyst-maintains-neutral-rating-with-58-target-price/48443/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CELG) Celgene Analyst Maintains Neutral Recommendation</title>
		<link>http://www.stockbloghub.com/2010/08/18/celg-celgene-analyst-maintains-neutral-recommendation/48249</link>
		<comments>http://www.stockbloghub.com/2010/08/18/celg-celgene-analyst-maintains-neutral-recommendation/48249#comments</comments>
		<pubDate>Wed, 18 Aug 2010 14:01:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDS]]></category>
		<category><![CDATA[Midas Inc.]]></category>
		<category><![CDATA[SuperGen Inc]]></category>
		<category><![CDATA[SUPG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48249</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Celgene Corporation (CELG) with a target price of $58. Celgene, founded in 1986 and headquartered in Summit, NJ, focuses on the discovery, development and commercialization of drugs in the areas of cancer and immune/inflammatory diseases. The company’s key growth engine is Revlimid, currently approved for myelodysplastic syndrome (MDS) and second-line multiple myeloma (MM). The company is expanding its label into other indications. The drug, which is approved in approximately 50 countries for treating patients suffering from MM who have received at least one prior therapy in combination with dexamethasone, recently received marketing approval in Japan for the same indication. Another important growth driver at Celgene is Vidaza, which is approved for the treatment of MDS. The third marketed product at Celgene is Thalomid, approved ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/18/celg-celgene-analyst-maintains-neutral-recommendation/48249/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ASH) Investing in the Biotech Sector: Here’s An Easy Way to Profit from Biotech Stocks</title>
		<link>http://www.stockbloghub.com/2009/11/11/ash-investing-in-the-biotech-sector-here%e2%80%99s-an-easy-way-to-profit-from-biotech-stocks/20305</link>
		<comments>http://www.stockbloghub.com/2009/11/11/ash-investing-in-the-biotech-sector-here%e2%80%99s-an-easy-way-to-profit-from-biotech-stocks/20305#comments</comments>
		<pubDate>Wed, 11 Nov 2009 21:51:36 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Chemicals - Major Diversified]]></category>
		<category><![CDATA[ARIA]]></category>
		<category><![CDATA[Ariad Pharmaceuticals Inc]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[IMGN]]></category>
		<category><![CDATA[Immunogen Inc]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[PARD]]></category>
		<category><![CDATA[Poniard Pharmaceuticals Inc]]></category>
		<category><![CDATA[SuperGen Inc]]></category>
		<category><![CDATA[SUPG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20305</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, November 11, 2009: Issue #1135 Investing in the biotech sector can be risky – no doubt about that. But you know what? There are a lot of ways to make money from biotech stocks, too. If you know what to look for, that is. Two obvious examples include: Picking the company behind the next breakthrough drug for cancer or Alzheimer’s. Digging out companies that are likely takeover targets (something my colleague Louis Basenese does expertly in his Takeover Trader service), or landing lucrative drug partnership deals, which send the stocks higher. But there’s another excellent way that shorter-term investors can grab gains and profit from biotech sector… Follow the Biotech Sector Conference Buzz Throughout the year, the biotech sector holds many key conferences where ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/11/ash-investing-in-the-biotech-sector-here%e2%80%99s-an-easy-way-to-profit-from-biotech-stocks/20305/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNTS) Top Performer for Wed: Santarus- Zacks #1 Rank Top Performers</title>
		<link>http://www.stockbloghub.com/2009/11/11/snts-top-performer-for-wed-santarus-zacks-1-rank-top-performers/20261</link>
		<comments>http://www.stockbloghub.com/2009/11/11/snts-top-performer-for-wed-santarus-zacks-1-rank-top-performers/20261#comments</comments>
		<pubDate>Wed, 11 Nov 2009 20:43:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Santarus Inc]]></category>
		<category><![CDATA[SNTS]]></category>
		<category><![CDATA[SuperGen Inc]]></category>
		<category><![CDATA[SUPG]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20261</guid>
		<description><![CDATA[Shares of Santarus, Inc. (SNTS) have moved north of 7.5% this morning, which has made this specialty biopharmaceutical company a top-performing Zacks #1 Rank stock. Last week, the company announced third-quarter results that included another positive earnings per share surprise, as well as a raised 2009 guidance. Earnings estimates have responded in kind by gaining in the past 7 trading days. Volume on Wednesday is approximately 317,000 shares, which is above the daily average of nearly 250,000. Santarus focuses on acquiring, developing and commercializing proprietary products for the prevention and treatment of gastrointestinal diseases and disorders. Its efforts are focused on ZEGERID® for the treatment of certain upper GI diseases and disorders, and GLUMETZA® to improve glycemic control in adults with type 2 diabetes. SNTS is 1 of 4 companies ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/11/snts-top-performer-for-wed-santarus-zacks-1-rank-top-performers/20261/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

